News
Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, for $561 million up front, with the hope that it can help transform a newly launched treatment for postpartum depression (PPD) into the indication's standard of care.
Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for ...
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...
After rejecting a buyout offer from its partner Biogen, the Cambridge firm is being acquired by Supernus Pharmaceuticals.
Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.
Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback